"Advanced hepatocellular carcinoma" trang 1 - tải miễn phí từ tailieuXANH
Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: A meta-analysis

Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: A meta-analysis
9    126    0
Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: A costeffectiveness analysis

Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: A costeffectiveness analysis
12    70    0
Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): Study protocol for a phase iii randomized controlled trial

Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): Study protocol for a phase iii randomized controlled trial
9    52    0
Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment

Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment
9    70    0
Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: A retrospective analysis of the CELESTIAL randomised controlled trial

Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: A retrospective analysis of the CELESTIAL randomised controlled trial
10    17    1
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial

Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial
10    46    0
Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: A case report

Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: A case report
7    51    0
A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma

A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma
7    63    0
Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: A retrospective cohort study

Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: A retrospective cohort study
9    67    0
Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization

Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization
9    75    0
Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): An open label, non-comparative, phase II trial

Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): An open label, non-comparative, phase II trial
10    54    0
Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: A budget impact analysis

Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: A budget impact analysis
9    86    0
A novel combined systemic inflammationbased score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization

A novel combined systemic inflammationbased score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization
9    59    0
Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: A prospective cohort study

Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: A prospective cohort study
10    54    0
First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: Preliminary results of safety, durable survival and immune biomarkers

First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: Preliminary results of safety, durable survival and immune biomarkers
11    53    0
Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib

Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib
13    52    0
Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: A single-arm meta-analysis based on prospective studies

Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: A single-arm meta-analysis based on prospective studies
13    58    0
Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: A retrospective study of routine clinical practice in multi-institutions

Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: A retrospective study of routine clinical practice in multi-institutions
7    47    0
Long non-coding RNAs HERH-1 and HERH-4 facilitate cyclin A2 expression and accelerate cell cycle progression in advanced hepatocellular carcinoma

Long non-coding RNAs HERH-1 and HERH-4 facilitate cyclin A2 expression and accelerate cell cycle progression in advanced hepatocellular carcinoma
16    51    1
Anti-PD-1 combined sorafenib versus antiPD-1 alone in the treatment of advanced hepatocellular cell carcinoma: A propensity score-matching study

Anti-PD-1 combined sorafenib versus antiPD-1 alone in the treatment of advanced hepatocellular cell carcinoma: A propensity score-matching study
8    187    2
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.